Janus kinase inhibitors in the treatment of vitiligo: a review
F Qi, F Liu, L Gao - Frontiers in immunology, 2021 - frontiersin.org
Vitiligo is a multifactorial reversible skin disorder characterized by distinct white patches that
result from melanocyte destruction. Activated CXCR3+ CD8+ T cells promote melanocyte …
result from melanocyte destruction. Activated CXCR3+ CD8+ T cells promote melanocyte …
Vitiligo: mechanisms of pathogenesis and treatment
ML Frisoli, K Essien, JE Harris - Annual review of immunology, 2020 - annualreviews.org
Vitiligo is an autoimmune disease of the skin that targets pigment-producing melanocytes
and results in patches of depigmentation that are visible as white spots. Recent research …
and results in patches of depigmentation that are visible as white spots. Recent research …
Targeting the Janus kinase family in autoimmune skin diseases
Autoimmune skin diseases are characterized by significant local and systemic inflammation
that is largely mediated by the Janus kinase (JAK)–signal transducer and activator of …
that is largely mediated by the Janus kinase (JAK)–signal transducer and activator of …
scRNA-seq of human vitiligo reveals complex networks of subclinical immune activation and a role for CCR5 in Treg function
KJ Gellatly, JP Strassner, K Essien, MA Refat… - Science translational …, 2021 - science.org
Vitiligo is an autoimmune skin disease characterized by the targeted destruction of
melanocytes by T cells. Cytokine signaling between keratinocytes and T cells results in …
melanocytes by T cells. Cytokine signaling between keratinocytes and T cells results in …
Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial
D Rosmarin, AG Pandya, M Lebwohl, P Grimes… - The Lancet, 2020 - thelancet.com
Background Vitiligo is a chronic autoimmune disease resulting in skin depigmentation and
reduced quality of life. There is no approved treatment for vitiligo repigmentation and current …
reduced quality of life. There is no approved treatment for vitiligo repigmentation and current …
Vitiligo, from pathogenesis to therapeutic advances: state of the art
F Diotallevi, H Gioacchini, E De Simoni… - International Journal of …, 2023 - mdpi.com
Vitiligo is an acquired hypopigmentation of the skin due to a progressive selective loss of
melanocytes; it has a prevalence of 1–2% and appears as rounded, well-demarcated white …
melanocytes; it has a prevalence of 1–2% and appears as rounded, well-demarcated white …
Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo
JM Richmond, JP Strassner, L Zapata Jr… - Science translational …, 2018 - science.org
Vitiligo is an autoimmune disease of the skin mediated by CD8+ T cells that kill melanocytes
and create white spots. Skin lesions in vitiligo frequently return after discontinuing …
and create white spots. Skin lesions in vitiligo frequently return after discontinuing …
[HTML][HTML] Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3
K Boniface, C Jacquemin, AS Darrigade… - Journal of Investigative …, 2018 - Elsevier
Vitiligo is a chronic autoimmune depigmenting skin disorder that results from a loss of
melanocytes. Multiple combinatorial factors have been involved in disease development …
melanocytes. Multiple combinatorial factors have been involved in disease development …
Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
Background Vitiligo is an autoimmune disease in which cutaneous depigmentation occurs.
Existing therapies are often inadequate. Prior reports have shown benefit of the Janus …
Existing therapies are often inadequate. Prior reports have shown benefit of the Janus …
Clinical features, immunopathogenesis, and therapeutic strategies in vitiligo
Y Wang, S Li, C Li - Clinical Reviews in Allergy & Immunology, 2021 - Springer
Vitiligo is an autoimmune disease of the skin characterized by epidermal melanocyte loss
resulting in white patches, with an approximate prevalence of 0.5–2% worldwide. Several …
resulting in white patches, with an approximate prevalence of 0.5–2% worldwide. Several …